Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism

Oncotarget

Volumn 6, Issue 35, 2015, Pages 37200-37215

  Sureban, Sripathi M ^a,c,d   Madhoun, Mohammad F ^a   May, Randal ^a,c   Qu, Dongfeng ^a,c,d   Ali, Naushad ^a,c,d   Fazili, Javid ^a,c   Weygant, Nathaniel ^a   Chandrakesan, Parthasarathy ^a,d   Ding, Kai ^b   Lightfoot, Stanley A ^a   Houchen, Courtney W ^a,c,d,e  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Peggy and Charles Stephenson Oklahoma Cancer Center   (United States)

^e NONE   (United States)

Author keywords

Biomarker; Circulating DCLK1; Cirrhosis; HCC; MiRNA

Indexed keywords

DOUBLECORTIN LIKE KINASE 1; KRUPPEL LIKE FACTOR 4; MICRORNA; MICRORNA 143; MICRORNA 145; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA LET 7A; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHOTRANSFERASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; DCLK1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BLOOD; CANCER STEM CELL; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC DATABASE; GENETIC TRANSFECTION; GENETICS; LIVER NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHENOTYPE; PROCEDURES; RETROSPECTIVE STUDY; RNA INTERFERENCE; RNAI THERAPEUTICS; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DATABASES, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICE, NUDE; MICRORNAS; NEOPLASTIC STEM CELLS; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; RETROSPECTIVE STUDIES; RNA INTERFERENCE; RNAI THERAPEUTICS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR BURDEN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84947793103     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5808     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010; 7:7.
2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. Journal of clinical gastroenterology. 2002; 35:S72-78.
3. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004; 127:S72-78.
4. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998; 28:751-755.
5. Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, Weitz J. Hepatocellular carcinoma: current management and perspectives for the future. Annals of surgery. 2011; 253:453-469.
6. Hoffe SE, Finkelstein SE, Russell MS, Shridhar R. Nonsurgical options for hepatocellular carcinoma: evolving role of external beam radiotherapy. Cancer control: journal of the Moffitt Cancer Center. 2010; 17:100-110.
7. Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. Journal of clinical oncology? official journal of the American Society of Clinical Oncology. 2008; 26:2795-2799.
8. Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. The Journal of Clinical Investigation. 2013; 123:1911-1918.
9. Lee TK, Castilho A, Ma S, Ng IO. Liver cancer stem cells: implications for a new therapeutic target. Liver Int. 2009; 29:955-965.
10. Turner R, Lozoya O, Wang Y, Cardinale V, Gaudio E, Alpini G, Mendel G, Wauthier E, Barbier C, Alvaro D, Reid LM. Human hepatic stem cell and maturational liver lineage biology. Hepatology. 2011; 53:1035-1045.
11. Chow EK, Fan LL, Chen X, Bishop JM. Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells. Hepatology. 2012; 56:1331-1341.
12. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell stem cell. 2011; 9:50-63.
13. Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, Zhao X, Andersen JB, Ye QH, Jia HL, Qin LX, Yamashita T, Woo HG, Kim YJ, Kaneko S, Tang ZY, et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology. 2012; 56:1792-1803.
14. Giannakis M, Chen SL, Karam SM, Engstrand L, Gordon JI. Helicobacter pylori evolution during progression from chronic atrophic gastritis to gastric cancer and its impact on gastric stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:4358-4363.
15. May R, Riehl TE, Hunt C, Sureban SM, Anant S, Houchen CW. Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. Stem cells. 2008; 26:630-637.
16. Nakanishi Y, Seno H, Fukuoka A, Ueo T, Yamaga Y, Maruno T, Nakanishi N, Kanda K, Komekado H, Kawada M, Isomura A, Kawada K, Sakai Y, Yanagita M, Kageyama R, Kawaguchi Y, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nature genetics. 2013; 45:98-103.
17. Ali N, Allam H, May R, Sureban SM, Bronze MS, Bader T, Umar S, Anant S, Houchen CW. Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. Journal of Virology. 2011; 85:12292-12303.
18. Ali N, Chandrakesan P, Nguyen CB, Husain S, Gillaspy AF, Huycke M, Berry WL, May R, Qu D, Weygant N, Sureban SM, Bronze MS, Dhanasekaran DN, Houchen CW. Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases. Oncotarget. 2015; 6:20327-20344. doi: 10.18632/oncotarget.3972.
19. Sureban SM, May R, Lightfoot SA, Hoskins AB, Lerner M, Brackett DJ, Postier RG, Ramanujam R, Mohammed A, Rao CV, Wyche JH, Anant S, Houchen CW. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer research. 2011; 71:2328-2338.
20. Sureban SM, May R, Mondalek FG, Qu D, Ponnurangam S, Pantazis P, Anant S, Ramanujam RP, Houchen CW. Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. Journal of nanobiotechnology. 2011; 9:40.
21. Sureban SM, May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier RG, Houchen CW. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PloS one. 2013; 8:e73940.
22. Sureban SM, May R, Ramalingam S, Subramaniam D, Natarajan G, Anant S, Houchen CW. Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology. 2009; 137:649-659, e641-642.
23. Sureban SM, May R, Weygant N, Qu D, Chandrakesan P, Bannerman-Menson E, Ali N, Pantazis P, Westphalen CB, Wang TC, Houchen CW. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer letters. 2014; 351:151-161.
24. Michalopoulos GK. Liver regeneration. Journal of cellular physiology. 2007; 213:286-300.
25. Chandrakesan P, Weygant N, May R, Qu D, Chinthalapally HR, Sureban SM, Ali N, Lightfoot SA, Umar S, Houchen CW. DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition. Oncotarget. 2014; 5:9269-9280.
26. Lata J. Chronic liver diseases as liver tumor precursors. Digestive diseases. 2010; 28:596-599.
27. Minguez B, Lachenmayer A. Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Disease markers. 2011; 31:181-190.
28. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nature reviews Gastroenterology & hepatology. 2010; 7:448-458.
29. Tian H, Biehs B, Warming S, Leong KG, Rangell L, Klein OD, de Sauvage FJ. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature. 2011; 478:255-259.
30. Gerbe F, van Es JH, Makrini L, Brulin B, Mellitzer G, Robine S, Romagnolo B, Shroyer NF, Bourgaux JF, Pignodel C, Clevers H, Jay P. Distinct ATOH1 and Neurog3 requirements define tuft cells as a new secretory cell type in the intestinal epithelium. The Journal of cell biology. 2011; 192:767-780.
31. The Cancer Genome Atlas (TCGA)-Liver Hepatocellular Carcinoma (LIHC). https://tcga-datancinihgov/tcga/tcgaCancerDetailsjsp?diseaseType=LIHC&diseaseName=Liver%20hepatocellular%20carcinoma.
32. Salt MB, Bandyopadhyay S, McCormick F. Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer discovery. 2014; 4:186-199.
33. Mondalek FG, Ponnurangam S, Govind J, Houchen C, Anant S, Pantazis P, Ramanujam RP. Inhibition of angiogenesis-and inflammation-inducing factors in human colon cancer cells in vitro and in ovo by free and nanoparticle-encapsulated redox dye, DCPIP. J Nanobiotechnology. 2010; 8:17.